
New in @JCO_ASCO! Following KEYNOTE-867, which found no survival benefit and greater toxicity with pembrolizumab + SBRT, MSK's Drs. Shaverdian & Riely examine the path forward for immunotherapy in early-stage NSCLC. 🎯 Risk, biology & timing matter. ascopubs.org/doi/10.1200/JCO…

























